Publication | Open Access

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Radiation MedicineRadiation TherapyMedicineAdvanced Soft-tissue SarcomaRadiopharmaceutical TherapyRadiotherapy Versus RadiotherapyBiomedical EngineeringFirst-in-class Radioenhancer HafniumOncologyRadiation OncologyNuclear MedicineRadiologyHealth Sciences